MDWD
$17.40
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally.
Intraday
Recent News
MediWound Q4 Earnings Call Highlights
MediWound (NASDAQ:MDWD) executives said 2025 marked a “pivotal year” for the company, highlighting progress in its late-stage EscharEx chronic wound program and the completion of an expanded manufacturing facility for NexoBrid, while also acknowledging revenue headwinds tied to U.S. government disru
MediWound Ltd. Q4 2025 Earnings Call Summary
Moby summary of MediWound Ltd.'s Q4 2025 earnings call
MediWound (MDWD) Q4 2025 Earnings Call Transcript
Barry Wolfenson, EVP of Strategy and Co-Development, is also participating in today's call. Following our prepared remarks, we will open the call for Q&A. Now I would like to turn the call over to Ofer Gonen, Chief Executive Officer of MediWound Ltd. Ofer?
MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of +14.07% and -10.76%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
MediWound: Q4 Earnings Snapshot
YAVNE, Israel (AP) — MediWound Ltd. (MDWD) on Thursday reported a loss of $7.2 million in its fourth quarter. On a per-share basis, the Yavne, Israel-based company said it had a loss of 56 cents. The results topped Wall Street expectations.